Cancer Gene Therapy Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)
Description
The global cancer gene therapy market was valued at USD 4.64 Billion in 2024 driven by the advancements in immune-oncology therapies across the globe. It is expected to grow at a CAGR of 18.90% during the forecast period of 2025-2034 and attain a market value of USD 26.20 Billion by 2034 .
Global Cancer Gene Therapy Market Overview
Cancer gene therapy works by changing and substituting defective genes to treat or prevent cancer. The market is experiencing rapid growth, driven by CRISPR-9, rising cancer rates, and advancements in personalized medicine. Other market trends involve the integration of AI for enhanced diagnosis and increased funding to promote innovation. These various characteristics are expanding the market by offering effective solutions for previously unaddressed needs, which in turn improves research and development and promotes commercialization.
Global Cancer Gene Therapy Market Growth Drivers
Rising Prevalence of Cancer Drives Market Growth
Due to the rising number of cancer cases worldwide, there is a growing need for new, advanced treatments. According to the American Cancer Society, 1,958,310 new cancer cases were detected, and 609,820 cancer fatalities took place in the United States in 2023. Gene therapy provides personalized and targeted treatments, addressing areas where traditional therapies are ineffective. Hence, the increasing number of patients is boosting market growth by motivating research and development as well as commercialization activities.
Global Cancer Gene Therapy Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Advancements in Gene Editing Technologies
Technologies such as CRISPR-Cas9 improve the accuracy and efficiency of cancer gene treatments. This has expedited research and development efforts and testing of new treatments, attracting significant financial backing. The increasing reliability and effectiveness of these treatments are leading to growth in the market, resulting in expanded usage and increased demand.
Integration of Artificial Intelligence (AI)
AI simplifies the identification of new cancer gene treatments by examining intricate genetic information, lowering development time and expenses. This enhances the precision of diagnoses and the effectiveness of treatments. AI's efficiency and innovation significantly boost the growth and competitiveness of the cancer gene therapy market.
Demand for Personalized Medicine
Another notable trend in the market is the rising need for personalized medicine. Advancements in understanding biomarkers and genomics are enabling the development of personalized drugs based on an individual's genetic profile, resulting in better treatment results, and promoting growth in the market.
Surge in Funding and Investments
Governments and private organizations are providing more support to pharmaceutical companies and research centers in developing new products for the global market.
Global Cancer Gene Therapy Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
Market Segmentation Based on the Indication Set to Witness Substantial Growth
Based on indication, the market is segmented into breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, prostate cancer, and others. Among these, breast cancer is the leading cancer type in the market because of its rising global incidence and the growing emphasis on targeted therapy solutions. Gene therapies for breast cancer target genetic mutations, providing personalized and efficient treatments. This led to significant funding in R&D, leading to many clinical trials and approvals.
Global Cancer Gene Therapy Market Analysis by Region
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is projected to lead the market due to the presence of large pharmaceutical companies and significant healthcare spending. Strong research endeavors and support from the government for cancer research are helping to grow the local market.
Leading Players in the Global Cancer Gene Therapy Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bristol-Myers Squibb Company
Based in New York, the company holds a significant presence in the immuno-oncology research domain. One of their notable products include Abecma (idecabtagene vicleucel) is a CAR T-cell therapy approved for treating relapsed or refractory multiple myeloma in the field of cancer gene therapy.
Elevate Bio Inc.
Elevate Bio Inc. is an international biotech corporation that focuses on cell and gene treatments. The headquarters of the company are in Massachusetts. Their main priority is to create and produce groundbreaking treatments for a range of illnesses, such as cancer. ElevateBio works with various partners to progress gene therapies for various types of cancer, utilizing their knowledge in gene editing and cell engineering.
Abeona Therapeutics Inc.
The company was established in New York and is in the process of creating cell and gene therapies for severe illnesses as a clinical-stage biopharmaceutical firm. Their lineup consists of experimental gene therapies for uncommon genetic disorders and specific cancers, making use of their proficiency in adeno-associated virus (AAV) vector technologies to create focused treatments.
Bluebird Bio Inc.
Bluebird Bio Inc. is an international biotech company headquartered in Massachusetts. In partnership with Bristol-Myers Squibb, they have created CAR T-cell treatments that focus on cancer markers, such as idecabtagene vicleucel (Abecma), to address multiple myeloma.
Other companies include Asklepios BioPharmaceutical Inc., NantKwest, Inc., Glaxo Smith Kline Inc., and Genelux Corporation.
Key Questions Answered in the Global Cancer Gene Therapy Market
Global Cancer Gene Therapy Market Overview
Cancer gene therapy works by changing and substituting defective genes to treat or prevent cancer. The market is experiencing rapid growth, driven by CRISPR-9, rising cancer rates, and advancements in personalized medicine. Other market trends involve the integration of AI for enhanced diagnosis and increased funding to promote innovation. These various characteristics are expanding the market by offering effective solutions for previously unaddressed needs, which in turn improves research and development and promotes commercialization.
Global Cancer Gene Therapy Market Growth Drivers
Rising Prevalence of Cancer Drives Market Growth
Due to the rising number of cancer cases worldwide, there is a growing need for new, advanced treatments. According to the American Cancer Society, 1,958,310 new cancer cases were detected, and 609,820 cancer fatalities took place in the United States in 2023. Gene therapy provides personalized and targeted treatments, addressing areas where traditional therapies are ineffective. Hence, the increasing number of patients is boosting market growth by motivating research and development as well as commercialization activities.
Global Cancer Gene Therapy Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Advancements in Gene Editing Technologies
Technologies such as CRISPR-Cas9 improve the accuracy and efficiency of cancer gene treatments. This has expedited research and development efforts and testing of new treatments, attracting significant financial backing. The increasing reliability and effectiveness of these treatments are leading to growth in the market, resulting in expanded usage and increased demand.
Integration of Artificial Intelligence (AI)
AI simplifies the identification of new cancer gene treatments by examining intricate genetic information, lowering development time and expenses. This enhances the precision of diagnoses and the effectiveness of treatments. AI's efficiency and innovation significantly boost the growth and competitiveness of the cancer gene therapy market.
Demand for Personalized Medicine
Another notable trend in the market is the rising need for personalized medicine. Advancements in understanding biomarkers and genomics are enabling the development of personalized drugs based on an individual's genetic profile, resulting in better treatment results, and promoting growth in the market.
Surge in Funding and Investments
Governments and private organizations are providing more support to pharmaceutical companies and research centers in developing new products for the global market.
Global Cancer Gene Therapy Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
- Gene Transfer
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Others
- Breast Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Lung Cancer
- Liver Cancer
- Prostate Cancer
- Others
- Hospitals
- Cancer Centers
- Research and Academic Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Segmentation Based on the Indication Set to Witness Substantial Growth
Based on indication, the market is segmented into breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, prostate cancer, and others. Among these, breast cancer is the leading cancer type in the market because of its rising global incidence and the growing emphasis on targeted therapy solutions. Gene therapies for breast cancer target genetic mutations, providing personalized and efficient treatments. This led to significant funding in R&D, leading to many clinical trials and approvals.
Global Cancer Gene Therapy Market Analysis by Region
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is projected to lead the market due to the presence of large pharmaceutical companies and significant healthcare spending. Strong research endeavors and support from the government for cancer research are helping to grow the local market.
Leading Players in the Global Cancer Gene Therapy Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bristol-Myers Squibb Company
Based in New York, the company holds a significant presence in the immuno-oncology research domain. One of their notable products include Abecma (idecabtagene vicleucel) is a CAR T-cell therapy approved for treating relapsed or refractory multiple myeloma in the field of cancer gene therapy.
Elevate Bio Inc.
Elevate Bio Inc. is an international biotech corporation that focuses on cell and gene treatments. The headquarters of the company are in Massachusetts. Their main priority is to create and produce groundbreaking treatments for a range of illnesses, such as cancer. ElevateBio works with various partners to progress gene therapies for various types of cancer, utilizing their knowledge in gene editing and cell engineering.
Abeona Therapeutics Inc.
The company was established in New York and is in the process of creating cell and gene therapies for severe illnesses as a clinical-stage biopharmaceutical firm. Their lineup consists of experimental gene therapies for uncommon genetic disorders and specific cancers, making use of their proficiency in adeno-associated virus (AAV) vector technologies to create focused treatments.
Bluebird Bio Inc.
Bluebird Bio Inc. is an international biotech company headquartered in Massachusetts. In partnership with Bristol-Myers Squibb, they have created CAR T-cell treatments that focus on cancer markers, such as idecabtagene vicleucel (Abecma), to address multiple myeloma.
Other companies include Asklepios BioPharmaceutical Inc., NantKwest, Inc., Glaxo Smith Kline Inc., and Genelux Corporation.
Key Questions Answered in the Global Cancer Gene Therapy Market
- What was the global cancer gene therapy market value in 2024?
- What is the global cancer gene therapy market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the therapy type?
- What is the market breakup based on the indication?
- What is the market breakup based on the end user?
- What are the major factors aiding the cancer gene therapy market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major cancer gene therapy market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the cancer gene therapy market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- How does oncolytic virotherapy work in treating cancer?
- Which cancer indication dominates the cancer gene therapy market?
- Why are hospitals significant end-users of cancer gene therapy?
- How is the Asia Pacific region contributing to the growth of the cancer gene therapy market?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cancer Gene Therapy Market Overview
- 3.1 Global Cancer Gene Therapy Market Historical Value (2018-2024)
- 3.2 Global Cancer Gene Therapy Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Cancer Gene Therapy Market Landscape*
- 5.1 Global Cancer Gene Therapy Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Cancer Gene Therapy Market: Product Landscape
- 5.2.1 Analysis by Therapy Type
- 5.2.2 Analysis by Indication
- 6 Global Cancer Gene Therapy Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Cancer Gene Therapy Market Segmentation (218-2034)
- 7.1 Global Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 7.1.1 Market Overview
- 7.1.2 Gene Transfer
- 7.1.3 Gene Induced Immunotherapy
- 7.1.4 Oncolytic Virotherapy
- 7.1.5 Others
- 7.2 Global Cancer Gene Therapy Market (2018-2034) by Indication
- 7.2.1 Market Overview
- 7.2.2 Breast Cancer
- 7.2.3 Ovarian Cancer
- 7.2.4 Pancreatic Cancer
- 7.2.5 Lung Cancer
- 7.2.6 Liver Cancer
- 7.2.7 Prostate Cancer
- 7.2.8 Others
- 7.3 Global Cancer Gene Therapy Market (2018-2034) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospitals
- 7.3.3 Cancer Centers
- 7.3.4 Research and Academic Institutes
- 7.3.5 Others
- 7.4 Global Cancer Gene Therapy Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Cancer Gene Therapy Market (218-2034)
- 8.1 North America Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 8.1.1 Market Overview
- 8.1.2 Gene Transfer
- 8.1.3 Gene Induced Immunotherapy
- 8.1.4 Oncolytic Virotherapy
- 8.1.5 Others
- 8.2 North America Cancer Gene Therapy Market (2018-2034) by Indication
- 8.2.1 Market Overview
- 8.2.2 Breast Cancer
- 8.2.3 Ovarian Cancer
- 8.2.4 Pancreatic Cancer
- 8.2.5 Lung Cancer
- 8.2.6 Liver Cancer
- 8.2.7 Prostate Cancer
- 8.2.8 Others
- 8.3 North America Cancer Gene Therapy Market (2018-2034) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospitals
- 8.3.3 Cancer Centers
- 8.3.4 Research and Academic Institutes
- 8.3.5 Others
- 8.4 North America Cancer Gene Therapy Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe Cancer Gene Therapy Market (218-2034)
- 9.1 Europe Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 9.1.1 Market Overview
- 9.1.2 Gene Transfer
- 9.1.3 Gene Induced Immunotherapy
- 9.1.4 Oncolytic Virotherapy
- 9.1.5 Others
- 9.2 Europe Cancer Gene Therapy Market (2018-2034) by Indication
- 9.2.1 Market Overview
- 9.2.2 Breast Cancer
- 9.2.3 Ovarian Cancer
- 9.2.4 Pancreatic Cancer
- 9.2.5 Lung Cancer
- 9.2.6 Liver Cancer
- 9.2.7 Prostate Cancer
- 9.2.8 Others
- 9.3 Europe Cancer Gene Therapy Market (2018-2034) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospitals
- 9.3.3 Cancer Centers
- 9.3.4 Research and Academic Institutes
- 9.3.5 Others
- 9.4 Europe Cancer Gene Therapy Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific Cancer Gene Therapy Market (218-2034)
- 10.1 Asia Pacific Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 10.1.1 Market Overview
- 10.1.2 Gene Transfer
- 10.1.3 Gene Induced Immunotherapy
- 10.1.4 Oncolytic Virotherapy
- 10.1.5 Others
- 10.2 Asia Pacific Cancer Gene Therapy Market (2018-2034) by Indication
- 10.2.1 Market Overview
- 10.2.2 Breast Cancer
- 10.2.3 Ovarian Cancer
- 10.2.4 Pancreatic Cancer
- 10.2.5 Lung Cancer
- 10.2.6 Liver Cancer
- 10.2.7 Prostate Cancer
- 10.2.8 Others
- 10.3 Asia Pacific Cancer Gene Therapy Market (2018-2034) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospitals
- 10.3.3 Cancer Centers
- 10.3.4 Research and Academic Institutes
- 10.3.5 Others
- 10.4 Asia Pacific Cancer Gene Therapy Market (2018-2034) by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America Cancer Gene Therapy Market (218-2034)
- 11.1 Latin America Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 11.1.1 Market Overview
- 11.1.2 Gene Transfer
- 11.1.3 Gene Induced Immunotherapy
- 11.1.4 Oncolytic Virotherapy
- 11.1.5 Others
- 11.2 Latin America Cancer Gene Therapy Market (2018-2034) by Indication
- 11.2.1 Market Overview
- 11.2.2 Breast Cancer
- 11.2.3 Ovarian Cancer
- 11.2.4 Pancreatic Cancer
- 11.2.5 Lung Cancer
- 11.2.6 Liver Cancer
- 11.2.7 Prostate Cancer
- 11.2.8 Others
- 11.3 Latin America Cancer Gene Therapy Market (2018-2034) by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Cancer Centers
- 11.3.4 Research and Academic Institutes
- 11.3.5 Others
- 11.4 Latin America Cancer Gene Therapy Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 11.4.4 Others
- 12 Middle East and Africa Cancer Gene Therapy Market (218-2034)
- 12.1 Middle East and Africa Cancer Gene Therapy Market (2018-2034) by Therapy Type
- 12.1.1 Market Overview
- 12.1.2 Gene Transfer
- 12.1.3 Gene Induced Immunotherapy
- 12.1.4 Oncolytic Virotherapy
- 12.1.5 Others
- 12.2 Middle East and Africa Cancer Gene Therapy Market (2018-2034) by Indication
- 12.2.1 Market Overview
- 12.2.2 Breast Cancer
- 12.2.3 Ovarian Cancer
- 12.2.4 Pancreatic Cancer
- 12.2.5 Lung Cancer
- 12.2.6 Liver Cancer
- 12.2.7 Prostate Cancer
- 12.2.8 Others
- 12.3 Middle East and Africa Cancer Gene Therapy Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Cancer Centers
- 12.3.4 Research and Academic Institutes
- 12.3.5 Others
- 12.4 Middle East and Africa Cancer Gene Therapy Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Grants Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Application
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by NIH Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Drug Class of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Drug Class of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Abeona Therapeutics Inc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 Asklepios BioPharmaceutical Inc.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 NantKwest, Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 Bluebird bio Inc.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 Bristol-Myers Squibb
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 Elevate Bio Inc.
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Glaxo Smith Kline Inc.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 Genelux Corporation
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 19 Global Cancer Gene Therapy Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
